SIGA Technologies, Inc.

NasdaqGM SIGA

SIGA Technologies, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2024: USD 3.61 M

SIGA Technologies, Inc. Total Non-Current Liabilities is USD 3.61 M for the quarter ending September 30, 2024, a 3.26% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

SIGA Technologies, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2023 was USD 3.50 M, a -3.71% change year over year.
SIGA Technologies, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2022 was USD 3.63 M, a -63.94% change year over year.
SIGA Technologies, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2021 was USD 10.07 M, a -17.23% change year over year.
SIGA Technologies, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2020 was USD 12.16 M, a -86.24% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

NasdaqGM: SIGA

SIGA Technologies, Inc.

CEO	Dr. Diem Nguyen M.B.A., Ph.D.
IPO Date	Sept. 10, 1997
Location	United States
Headquarters	31 East 62nd Street
Employees	45
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies Vaccines

Description

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.

Key trends

Past 5 years